Please assess the completion status of the following clinical trial:

Trial Title: A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected~* Subject must be a candidate for phototherapy and/or systemic therapy~Exclusion Criteria:~* Subject has non-plaque psoriasis or drug-induced psoriasis~* Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is longer, prior to first dose of study drug~* Subject has a positive TB skin test within 3 months of screening or at screening~* Subject has an abnormal chest x-ray

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): lowest dose
- Group 2 (Type: EXPERIMENTAL): low dose
- Group 3 (Type: EXPERIMENTAL): high dose
- Group 4 (Type: EXPERIMENTAL): highest dose
- Group 5 (Type: EXPERIMENTAL): medium dose
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).